Skip to content
GERICLINICS

Flashcards · Module 32

🛡️ Immunosenescence & Vaccinology

4 of 4 cards published · read by the site’s author on 21 November 2026

Thymic Involution & T-Cell Repertoire Shrinkage

Needs clinical review

The Shrinking Organ:

The thymus is where T-cells mature. With age it involutes, losing epithelial cells and filling with fat.

The T-Cell Consequences:

  • 📉 Fewer Naive T-Cells: fewer new naive CD4+ and CD8+ T-cells are made and T-cell diversity narrows, so responses to new pathogens weaken.

  • 📈 Memory Inflation: The T-cell pool becomes crowded with exhausted, terminally differentiated effector memory cells (often occupied by lifelong chronic Cytomegalovirus [CMV] infection).

  • Inverted CD4:CD8 Ratio: CD8+ cells outnumber CD4+ cells (ratio <1.0), part of the immune risk profile that predicted 2-year mortality in people aged 86–94.

One-Liner: Thymic involution replaces thymus tissue with fat, reducing new naive T-cell production and narrowing the T-cell repertoire.
Sources checked (5) · 18 November 2026

Note: On chest CT of middle-aged adults aged 50-64 years, 59% already had complete fatty degeneration of the thymus and 25% had predominantly fatty attenuation. (Complete fatty degeneration of thymus associates with male sex, obesity and loss of circulating naïve CD8(+) T cells in a Swedish middle-aged population (2023))

Note: Age-related thymic degeneration reduces naive T-cell export and restricts peripheral T-cell receptor diversity, impairing responses to diverse pathogens. (Prolongevity hormone FGF21 protects against immune senescence by delaying age-related thymic involution (2016))

Note: Persistent CMV infection in older adults is associated with expansion of terminally differentiated effector memory T cells (TEMRA phenotype). (The inverted CD4/CD8 ratio and associated parameters in 66-year-old individuals: the Swedish HEXA immune study (2013))

Note: In clinical profiling, IRP positivity has been defined as CMV seropositivity together with a CD4/CD8 ratio < 1 or high proportions of senescent CD8+ T cells. (NK Cells Contribute to the Immune Risk Profile in Kidney Transplant Candidates (2019))

The Geriatric Vaccine Schedule: Pneumococcal, RSV & Flu

Needs clinical review

US (ACIP) Vaccine Recommendations for Adults Aged ≥65:

VaccineIndicationRecommended Regimen
PneumococcalAll PCV-naïve adults ≥50 (and adults 19–49 with risk conditions)PCV20 (Prevnar 20) or PCV21 (Capvaxive) single dose alone, OR PCV15 followed ≥1 year later by PPSV23
InfluenzaAnnual every autumn🥇 High-Dose Inactivated (Fluzone High-Dose), Recombinant (Flublok), or Adjuvanted (Fluad) — superior to standard dose!
RSV (Respiratory Syncytial Virus)All adults ≥75, AND adults 60–74 at increased risk for severe RSV diseaseSingle dose of RSV vaccine (Arexvy, Abrysvo, or mResvia) — no repeat dose currently recommended
ShinglesAdults ≥502 doses of Recombinant Zoster Vaccine (Shingrix) 2–6 months apart
COVID-19Annual autumn boosterUpdated formulation for prevailing variants
One-Liner: Adults ≥65 need single-dose PCV20 or PCV21 (routine from age ≥50; or PCV15+PPSV23), high-dose/recombinant/adjuvanted flu vaccine, universal RSV vaccination at ≥75 (60–74 if at risk), and 2-dose Shingrix.
Sources checked (6) · 18 November 2026

Note: If none of these three preferential vaccines is available at an opportunity for vaccine administration, any other age-appropriate influenza vaccine should be used. (Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-25 Influenza Season (2024))

Note: In older adults, the RSVpreF vaccine (Abrysvo) was associated with 18.2 extra cases of Guillain-Barré syndrome per million doses. (Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025-2026 (2025))

Note: ACIP also recommends 2 doses of recombinant zoster vaccine for immunodeficient or immunosuppressed adults aged ≥19 years. (Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022 (2022))

Note: Because SARS-CoV-2 circulates year-round and vaccine protection wanes, ACIP has also recommended an additional updated COVID-19 vaccine dose for adults aged ≥65 years (who accounted for 67% of COVID-19 hospitalizations during October 2023-January 2024). (Use of an Additional Updated 2023-2024 COVID-19 Vaccine Dose for Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024 (2024))

Note: Changes to the US vaccine advisory process in 2025 disrupted guidance; an independent review found the evidence still supports COVID-19, RSV and influenza vaccines for 2025–2026. (Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025-2026 (2025))

Blunted Vaccine Responses & Adjuvants: Why high-dose flu shots are preferred

Needs clinical review

The Immunologic Problem:

Given a standard flu shot, older adults are much less likely to respond than young adults: odds ratios of 0.24 to 0.59 for seroconversion and seroprotection.

The Two High-Tech Solutions:

  1. 💥 High-Dose Vaccine (Fluzone High-Dose): Contains 4 times the antigen (60 µg vs. 15 µg of hemagglutinin per strain). In adults ≥65 it cut laboratory-confirmed flu by a further 24% compared with standard dose!

  2. 🧲 Adjuvanted Vaccine (Fluad): Contains MF59 (an oil-in-water squalene emulsion) that recruits monocytes and prolongs antigen presentation at the injection site.

Board Rule:

For adults ≥65, prefer a high-dose, recombinant or adjuvanted vaccine; if none is available, give any age-appropriate flu vaccine rather than none.

One-Liner: Aging blunts antibody production; adults ≥65 should preferentially receive high-dose (4x antigen), recombinant, or adjuvanted flu shots (or any age-appropriate flu vaccine if none is available).
Sources checked (4) · 18 November 2026

Note: Across 31 antibody response studies, the adjusted odds ratio for seroconversion and seroprotection in older versus younger adults was 0.24 to 0.59, corresponding to estimated clinical vaccine efficacy of 17-53% in older adults versus 70-90% in younger adults. (Antibody response to influenza vaccination in the elderly: a quantitative review (2006))

Note: MF59 is an oil-in-water emulsion of squalene oil combined with a standard antigen dose in adjuvanted influenza vaccine for adults aged 65+ years. (An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population (2022))

Reactivation Tuberculosis in Older Adults: The "Booster Phenomenon"

Needs clinical review

The Presentation Shift:

Tuberculosis in older adults mostly results from reactivation of latent infection acquired decades earlier.

  • Classic cavitary apical lung disease with night sweats may be completely absent!

  • Instead, lesions are more often in the lower lung fields, and atypical, non-specific symptoms delay diagnosis.

The PPD "Two-Step" Booster Phenomenon (The Clinical Trap!):

  1. An older adult has latent TB, but their cell-mediated immunity is dormant.

  2. You place a single PPD skin test → it reads 0 mm (NEGATIVE).

  3. However, that first PPD test "wakes up" (boosts) their immune memory!

  4. One year later, you test them again → PPD reads 14 mm (POSITIVE)!

  5. 🚨 THE MISTAKE: The clinician panics and thinks: "New hospital TB transmission!"

  6. The Reality: It is the Booster Effect, NOT a new infection.

  7. The Prevention: Use Two-Step PPD Testing at baseline: place a PPD; if negative, repeat a second PPD 1 to 3 weeks later to establish their true baseline!

One-Liner: Tuberculin reactivity wanes with age; two-step testing at baseline, for people who will be retested, prevents misreading the "booster phenomenon" as a new infection.
Sources checked (8) · 18 November 2026

Note: In a cohort comparing elderly (≥65 years) and younger patients with smear-positive pulmonary TB, night sweats were significantly less frequent in older adults (20.8% vs. 34.9%, p = 0.04). (Differences in clinical, radiological and laboratory parameters between elderly and young patients with newly diagnosed smear-positive pulmonary tuberculosis in Vietnam (2025))

Note: Atypical and nonspecific clinical manifestations of TB in older adults frequently delay diagnosis and treatment, contributing to higher morbidity and mortality. (Tuberculosis and aging: a global health problem (2001))

Note: Interferon-gamma release assays (QuantiFERON-TB Gold In-Tube and T-SPOT.TB) are also FDA-approved aids for diagnosing latent and active M. tuberculosis infection. (Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010 (2010))